PRS13 COST-UTILITY ANALYSIS OF MACITENTAN IN COMPARISON WITH BOSENTAN IN PULMONARY ATRIAL HYPERTENSION (PAH)
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2504
https://www.valueinhealthjournal.com/article/S1098-3015(19)34882-X/fulltext
Section Title :
Section Order :
12188
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34882-X&doi=10.1016/j.jval.2019.09.2504